ANZCTR - Registration

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12614001000695

Ethics application status

Approved

Date submitted

5/09/2014

Date registered

16/09/2014

Date last updated

18/11/2015

Type of registration

Prospectively registered

Titles & IDs

Public title

Experiences with a new regional citrate anticoagulation protocol for continuous venovenous hemofiltration using a phosphate containing replacement solution in critically ill patients

Scientific title

Regional citrate anticoagulation for continuous venovenous hemofiltration using Prismocitrate 18/0 and a phosphate containing replacement solution (Phoxilium) for critically ill patients: Effect on filter life and acid-base changes

Secondary ID [1]

Nil

Universal Trial Number (UTN)

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Acute kidney injury

Critical illness

Condition category

Condition code

Renal and Urogenital

Kidney disease

Intervention/exposure

Study type

Observational

Patient registry

False

Target follow-up duration

Target follow-up type

Description of intervention(s) / exposure

Citrate CVVH was performed using either of the following 2 machines: Prismaflex machine (Gambro-Hospal) with a high-flux hemofilter (HF 1400/ ST 100) or MultiFiltrate (Fresenius Medical Care) with the Ultraflux AV 600S hemofilter. The blood flow rate was maintained at 110ml/min, Prismocitrate 18/0 solution running at a fixed rate of 1250 ml/h as predilution replacement fluid, Phoxilium solution at 1250ml/h as post-dilution replacement fluid. Blood samples for urea/ creatinine/ acid-base/ total calcium/ ionized calcium/ pre-filter ionzied calcium/ post-filter ionized calcium were taken at time 0, 2, 4, 8, 16, 24, 32, 40, 48, 56, 64 and 72hrs for monitoring purpose. Additional blood tests were performed as indicated based on clinical indications. Concentrated calcium infusion (10% Calcium chloride) was infused via a separate central line and was titrated to achieve a systemic iCa level of 1–1.2 mmol/L. The fluid withdrawal rate was adjusted to achieve the desired fluid balance. The circuit was run for 72 h unless there was filter clotting, transportation outside ICU, or the patient did not require additional CRRT.

Intervention code [1]

Not applicable

Comparator / control treatment

Uncontrolled

Control group

Uncontrolled

Outcomes

Primary outcome [1]

Hemofilter life span as determined by time to circuit clotting criteria reached and no more than 72 hours

Timepoint [1]

Circuit clotting criteria: hourly inspections for visible extracorporeal circuit / filter clotting, or transmembrane pressure >450mmHg, up to a maximum of 72 hours

Secondary outcome [1]

Serum urea changes

Timepoint [1]